Tumor necrosis factor (TNF) inhibitors led to no significant difference in survival or respiratory-related hospitalizations compared with non-TNF inhibitors, in patients with rheumatoid ...

Patients with ankylosing spondylitis who were exposed to tumor necrosis factor (TNF) inhibitors had an approximately 30% lower risk for cardiovascular events than those who had never been exposed to ...

Please provide your email address to receive an email when new articles are posted on . Switching from a TNF inhibitor to upadacitinib was superior to cycling TNF inhibitors. Upadacitinib outcomes ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The median survival time of first-line anti-TNF therapy ...

Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...

Children with nonsystemic juvenile idiopathic arthritis who initiated TNF inhibitors when aged 2 years or less showed significant and sustained improvements in disease activity. Early initiation of ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease. A new study published recently in the journal Gut shows children with Crohn's who ...

PALM BEACH GARDENS, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc (“Forward”), a biotechnology company developing oral small molecule therapies for inflammation-driven diseases, ...